Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma

NCT04590248 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04590248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04590248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2020
Completion date
February 7, 2023
Enrollment
109 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

uterine serous carcinoma